Australia’s National Health and Medical Research Council (NHMRC) has proposed when clinicians may consider puberty-suppressing drugs for some transgender and gender-diverse people under 18, as public-service rules vary among states.
The consultation-stage advice says treatment may be considered when a young person wants it, has reached Tanner stage 2 or later, and has gender incongruence, whether or not the person is distressed. A clinician must also judge the young person suitable, with multidisciplinary input tailored to individual circumstances. The draft calls for decisions involving the young person, parents or carers, and clinicians.
NHMRC’s review examined 15 non-randomized studies with data from 12,756 people. It found low-certainty evidence of possible small improvements in mental and social functioning, but no eligible studies assessed death by suicide, fertility potential, bone fractures or functional bone-health outcomes. Prue Torrance, NHMRC acting CEO, said, “Puberty suppressants are one possible part of care.”
Queensland’s ministerial direction, effective Oct. 28, 2025, bars public hospital services from starting puberty blockers or gender-affirming hormone therapy for new patients under 18 with gender dysphoria. It defines a Current Patient as someone under 18 who began Stage 1 or Stage 2 treatment before Jan. 28, 2025; those patients may continue treatment when clinically indicated. The direction is due for review by Jan. 28, 2032.
The NT Government says its public health system does not offer puberty blockers or other hormone treatment. Australia’s federal government asked NHMRC to develop national guidance, while states and territories run public gender services and employ the clinicians.
Public consultation opened Sunday, Nov. 15, at 9 p.m. ET (1 p.m. AEDT Nov. 16) and closes at 9 p.m. ET Jan. 17, 2027 (1 p.m. AEDT Jan. 18). NHMRC expects to issue the full guidelines in 2028.



